Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657481 | 0.83 | DRD2 (0.45) | DRD2ALDH1A1GAAGFERPDK2 | |
| SCHEMBL4654931 | 0.81 | DRD2 (0.46) | DRD2ALDH1A1GAAGFERMAPT | |
| SCHEMBL4717744 | 0.81 | DRD2 (0.47) | DRD2PPARAALDH1A1PPARGMEN1 | |
| SCHEMBL4189987 | 0.80 | DRD2 (0.51) | DRD2ALDH1A1GAAGFERPDK2 | |
| SCHEMBL21882882 | 0.80 | DRD2 (0.66) | DRD2ALDH1A1GAAGFERCYP3A4 | |
| SCHEMBL4654990 | 0.77 | DRD2 (0.37) | DRD2ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL4183160 | 0.76 | DRD2 (0.47) | DRD2ALDH1A1GAAGFERPDK2 | |
| SCHEMBL4655922 | 0.76 | ALDH1A1 (0.54) | ALDH1A1GAAGFERPTGS1PDK2 | |
| SCHEMBL7419392 | 0.74 | ELANE (0.46) | DRD2ALDH1A1CYP3A4ALOX5NPC1 | |
| SCHEMBL7041553 | 0.73 | ALDH1A1 (0.57) | ALDH1A1GAAGFERPTGS1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996198-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | DRD2 1114/4885PPARA 2/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.